Business of Biotechnology: Advanced Concepts Short Course, Summer 2019

BOSTON, JUNE 18-27, 2019

RA Capital’s next course will be taught in Summer 2019.

Click to be notified when our application goes live.

NOTIFY ME Student Reviews

Live Discussions

Past Course Photo

Course Participants

  • Meg Krench, PhD (TA)
  • Jessica Sagers, PhD (TA)
  • Rebecca Fine, PhD (TA)
  • Will Orent, PhD (TA)
  • Ariel (Wei Hsi) Yeh
  • Abir Yamak
  • Yusuf Erkul
  • Anika Gupta
  • Anthony Zlaket
  • Brett Geiger
  • Christy Kuo
  • David Migl
  • David Thompson
  • Elaine Oberlick
  • Emeka Okoro
  • Hugo Caicedo
  • Ida Pavlichenko
  • Iris Braunstein
  • Jamie Zhan
  • Kevin Huang
  • Lena Afeyan
  • Michael Mazzola
  • Norah Owiti
  • Rachel Schecter
  • Soufiane Aboulhouda
  • Tanya Yatsunenko
  • Suan Tuang
  • Xiaobo Ke


  • LOCATION: Back Bay, Boston, MA
  • COST: Free
  • LECTURER: Peter Kolchinsky, Ph.D, Managing Partner, RA Capital


  • DISCUSSION: Tuesday, June 18, 2:00-4:00 PM
  • LECTURE 1: Thursday, June 20, 2:00-5:00 PM
  • LECTURE 2: Tuesday, June 25, 2:00-5:00 PM
  • LECTURE 3: Thursday, June 25, 2:00-5:00 PM
  • LECTURE 4: Thursday, June 27, 2:00-5:00 PM
  • PREP/READING TIME: Approx. 20 hours

“The course has debunked many myths for me, and motivated me to one day consider my future in the biotech space!”

– Hugo Caicedo, Summer 2019 Participant

View All Student Reviews

Session 1

Drug Pricing & The Biotech Social Contract


Read a series of articles about the biotech social contract and then, through that lens, write a short analysis of an article that is critical of biotech drug pricing practices. You will be paired with another student and exchange write-ups before coming to the pre-lecture discussion section.


Tuesday, 2:00-4:00pm

Discuss your drug pricing article analysis (where do you agree with the author and what do you think the author got wrong?) with your partner, the teaching assistant, and other students. Work on a combined analysis with your partner that uses the best of your ideas. This will also be an opportunity for you to meet the other students, teaching assistants, and the lecturer.


Thursday, 2:00-5:00pm

Come prepared to share your thoughts on the article that you and your partner analyzed. We’ll discuss how companies and investors think about drug pricing when they are considering whether to pursue a program. There will be lots of case studies. You’ll come away appreciating the implications of getting drug pricing reforms wrong but also which forms of price controls would actually make the industry more vibrant.


Stable and Unstable Business Models


Several articles and case studies. No written assignment.


TUESDAY, 2:00-5:00pm

You’ll hear lots of case studies. We’ll talk about when companies that appear diversified actually aren’t and how a successful clinical result can imperil a pipeline. You’ll come away appreciating how a company should think about constructing a pipeline in which there is at least some synergy among the programs as opposed to the whole being worth less than the sum of its parts.

Session 3

Financing Game Theory


A complex, data-rich presentation that we’ll discuss during the lecture. Also some articles and definitions of financing terms. No written assignment.


Thursday, 2:00-5:00pm

We’ll review case studies of how companies have tried to raise money in ways that defied conventions, including how crossover financing arose, why only one measure of “early-stage” vs “late-stage” really correlates with valuation (and it’s not what most people think), what about a deal gets investors to invest, why some companies end up having broken IPOs, and what does and doesn’t predict whether a company will have a successful first year in the public markets.


THURSDAY, 5:30-7:30pm (optional)

After the final lecture, we’ll have dinner and a tour of RA Capital with a demonstration of how we use our TechAtlas competitive landscape maps to identify technologies and companies that we think are compelling.After the final lecture, we’ll have dinner and a tour of RA Capital with a demonstration of how we use our TechAtlas competitive landscape maps to identify technologies and companies that we think are compelling.